Given that insulin resistance constitutes a critical pathophysiological mechanism in diabetes, based on the aforementioned experimental findings, we tentatively propose that stigmasterol may serve as a potential PPARG modulator for diabetic patients exhibiting significant insulin resistance. This evidence concerns the gene PPARG and diabetes mellitus.